AURKA and glioma: A recent Phase I study evaluated the association of stereotactic radiotherapy (FSRT) with alisertib, a 2nd generation Aurora A kinase (AURKA) inhibitor with anti-neoplastic and radio-sensitization activity, in recurrent high-grade glioma patients [187].